CD274 and neoplasm: Recent studies have shown that RSL-3-rich nanoparticles can promote the immunogenic death of tumor cells, while the combined treatment of blocking PD-L1 further enhanced the T lymphocytes infiltration within tumors (Song et al., 2021).